Select a medication above to begin.
acétyl-lévocarnitine
acetyl-L-carnitine
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- ADHD [Insufficient Evidence]
- age-related cognitive decline [Possibly Effective]
- alcohol withdrawal sx [Possibly Effective]
- Alzheimer dz [Possibly Effective]
- amenorrhea [Insufficient Evidence]
- amyotrophic lateral sclerosis [Insufficient Evidence]
- athletic performance [Insufficient Evidence]
- Bell palsy [Insufficient Evidence]
- bipolar disorder [Insufficient Evidence]
- carpel tunnel syndrome [Insufficient Evidence]
- cataracts [Insufficient Evidence]
- chronic fatigue syndrome [Insufficient Evidence]
- depression [Possibly Effective]
- diabetes mellitus [Insufficient Evidence]
- diabetic neuropathy [Possibly Effective]
- Down syndrome [Insufficient Evidence]
- dyslipidemia [Insufficient Evidence]
- fatigue, age-related [Possibly Effective]
- fatigue, cancer-related [Insufficient Evidence]
- fatigue, multiple sclerosis-related [Insufficient Evidence]
- female infertility [Insufficient Evidence]
- fibromyalgia [Insufficient Evidence]
- fragile X syndrome [Insufficient Evidence]
- frailty [Insufficient Evidence]
- hepatic encephalopathy [Insufficient Evidence]
- hepatotoxicity, toxin-induced [Insufficient Evidence]
- HTN [Insufficient Evidence]
- Lyme dz [Insufficient Evidence]
- male infertility [Possibly Effective]
- obesity [Insufficient Evidence]
- peripheral neuropathy [Insufficient Evidence]
- peripheral neuropathy, antiretroviral-assoc. [Insufficient Evidence]
- peripheral neuropathy, chemo-induced [Possibly Ineffective]
- Peyronie dz [Insufficient Evidence]
- polycystic ovary syndrome [Insufficient Evidence]
- schizophrenia [Insufficient Evidence]
- sciatica [Insufficient Evidence]
- skin aging [Insufficient Evidence]
- stroke [Insufficient Evidence]
- testosterone deficiency, age-related [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
age-related cognitive decline
- [Possibly Effective]
- Dose: 1500-2000 mg PO qd; Info: may give in divided doses
alcohol withdrawal sx
- [Possibly Effective]
- Dose: 1-3 g IV infusion over 3-4h/day x10 days, then 3 g PO qd
Alzheimer dz
- [Possibly Effective]
- Dose: 1500-3000 mg PO qd; Info: may give in divided doses
amyotrophic lateral sclerosis
- [Insufficient Evidence]
- Dose: 1000 mg PO tid; Info: used w/ riluzole
chronic fatigue syndrome
- [Insufficient Evidence]
- Dose: 2000 mg PO qd; Info: may give in divided doses
depression
- [Possibly Effective]
- Dose: 1000-4000 mg PO qd; Info: may give in divided doses
diabetic neuropathy
- [Possibly Effective]
- Dose: 1500-3000 mg PO qd; Alt: 1000 mg PO bid-tid; 500 mg PO tid; Info: may give doses >1500 mg/day in divided doses
fatigue, age-related
- [Possibly Effective]
- Dose: 2 g PO bid
fatigue, multiple sclerosis-related
- [Insufficient Evidence]
- Dose: 1000 mg PO bid
fibromyalgia
- [Insufficient Evidence]
- Dose: 1000 mg PO qd plus 500 mg IM qd x14 days, then 1500 mg PO qd; Alt: 500 mg PO bid-tid; Info: may give doses >1500 mg/day in divided doses
frailty
- [Insufficient Evidence]
- Dose: 1500 mg PO bid
hepatotoxicity, toxin-induced
- [Insufficient Evidence]
- Dose: 250 mg PO bid; Info: used w/ coenzyme Q10 and alpha-lipoic acid
male infertility
- [Possibly Effective]
- Dose: 50-1000 mg PO qd; Alt: 500 mg PO bid; Info: used w/ L-carnitine
male infertility, abacterial prostatovesiculoepididymitis-assoc.
- [Possibly Effective]
- Dose: 500 mg PO bid; Info: used w/ L-carnitine
peripheral neuropathy, antiretroviral-assoc.
- [Insufficient Evidence]
- Dose: 1000-1500 mg PO bid; Alt: 500-1000 mg IV/IM qd
Peyronie dz
- [Insufficient Evidence]
- Dose: 1000 mg PO bid
polycystic ovary syndrome
- [Insufficient Evidence]
- Dose: 1500 mg PO bid; Info: used w/ antidiabetic tx
schizophrenia
- [Insufficient Evidence]
- Dose: 1000 mg PO qd; Info: used w/ clozapine
sciatica
- [Insufficient Evidence]
- Dose: 1180 mg PO qd
stroke
- [Insufficient Evidence]
- Dose: 1000 mg PO/NG tid x3 days; Start: w/in 24h of sx onset; Info: used w/ standard tx in patients who were not candidates for reperfusion therapy
testosterone deficiency, age-related
- [Insufficient Evidence]
- Dose: 2000 mg PO qd; Info: used w/ propionyl-L-carnitine; may give in divided doses
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.